Drug data · shortage, price, volume

Diltiazem extended-release capsules: listed 15 months as a shortage, and the generic benchmark price rose 14% since 2021

The FDA has listed this drug as short in the past. The pharmacy benchmark says the generic capsule now costs $0.311 each, against $1.36 in 2013. Availability and price are different measures, so this page shows both over time.

FDA shortage list, 2026-11-05NADAC, November 2026Medicaid SDUDinferred monthno data
  1. The ER capsule was on the FDA list from December 2018 to February 2020, 15 months, and is not listed now.
  2. 62% of shortage listings since 2014 lasted as long as this one. The median lasts 21 months.
  3. A generic 120 mg capsule costs pharmacies $0.311 on the NADAC benchmark in November 2026, 14% above its 2021 median.
  4. Medicaid paid for 78,681 ER capsule prescriptions in Q4 2025, 3% fewer than in Q4 2021.

Not medical advice. This page reports public records about supply and pharmacy cost. Ask a pharmacist or prescriber about your own medication.

Three clocks on one timeline

Each lane uses the same monthly axis, so you can read across: when the FDA listed the ER capsule, what pharmacies were paying, and how many Medicaid prescriptions were filled.

on the listinferred across a missing captureno capture or no price$ per capsuleprescriptionspreliminary quarter

Swipe the chart sideways to see all 14 years.

Three clocks: FDA shortage list, pharmacy acquisition cost and Medicaid prescriptionsShared monthly timeline. Top lane: months the ER capsule was on the FDA shortage list. Middle lane: NADAC price per capsule by strength. Bottom lane: Medicaid prescriptions per quarter. 2014201520162017201820192020202120222023202420252026FDA shortage listER capsule, by name2013-01 to 2014-05: no capture of the FDA list for these months2014-09 to 2014-09: no capture of the FDA list for these months2016-02 to 2016-02: no capture of the FDA list for these months2018-10 to 2018-11: no capture of the FDA list for these months2018-12 to 2019-01: on the list (observed)2019-02 to 2019-04: on the list (inferred across a missing capture)2019-05 to 2020-02: on the list (observed)2024-10 to 2025-08: no capture of the FDA list for these monthsfirst listed Dec 2018Pharmacy costNADAC, $ per capsulebold = 120 mg generic$0$5$10$1.36 in 2013$0.311 nowMedicaid fillsprescriptions per quarterER capsule2013Q1: 5,108 prescriptions; unsuppressed state rows only2013Q2: 5,320 prescriptions; unsuppressed state rows only2013Q3: 5,169 prescriptions; unsuppressed state rows only2013Q4: 5,105 prescriptions; unsuppressed state rows only2014Q1: 5,515 prescriptions; unsuppressed state rows only2014Q2: 7,192 prescriptions; unsuppressed state rows only2014Q3: 8,377 prescriptions; unsuppressed state rows only2014Q4: 9,701 prescriptions; unsuppressed state rows only2015Q1: 10,776 prescriptions; unsuppressed state rows only2015Q2: 13,159 prescriptions; unsuppressed state rows only2015Q3: 17,130 prescriptions; unsuppressed state rows only2015Q4: 18,846 prescriptions; unsuppressed state rows only2016Q1: 19,384 prescriptions; unsuppressed state rows only2016Q2: 18,687 prescriptions; unsuppressed state rows only2016Q3: 18,436 prescriptions; unsuppressed state rows only2016Q4: 19,108 prescriptions; unsuppressed state rows only2017Q1: 20,041 prescriptions; unsuppressed state rows only2017Q2: 21,343 prescriptions; unsuppressed state rows only2017Q3: 20,209 prescriptions; unsuppressed state rows only2017Q4: 20,577 prescriptions; unsuppressed state rows only2018Q1: 20,501 prescriptions; unsuppressed state rows only2018Q2: 20,995 prescriptions; unsuppressed state rows only2018Q3: 21,119 prescriptions; unsuppressed state rows only2018Q4: 20,311 prescriptions; unsuppressed state rows only2019Q1: 20,207 prescriptions; unsuppressed state rows only2019Q2: 22,125 prescriptions; unsuppressed state rows only2019Q3: 25,618 prescriptions; unsuppressed state rows only2019Q4: 27,724 prescriptions; unsuppressed state rows only2020Q1: 29,172 prescriptions; unsuppressed state rows only2020Q2: 29,598 prescriptions; unsuppressed state rows only2020Q3: 35,434 prescriptions; unsuppressed state rows only2020Q4: 36,977 prescriptions; unsuppressed state rows only2021Q1: 54,673 prescriptions; unsuppressed state rows only2021Q2: 70,638 prescriptions; unsuppressed state rows only2021Q3: 77,724 prescriptions; unsuppressed state rows only2021Q4: 81,165 prescriptions; unsuppressed state rows only2022Q1: 81,612 prescriptions; unsuppressed state rows only2022Q2: 82,196 prescriptions; unsuppressed state rows only2022Q3: 84,741 prescriptions; unsuppressed state rows only2022Q4: 83,325 prescriptions; unsuppressed state rows only2023Q1: 84,296 prescriptions; unsuppressed state rows only2023Q2: 80,163 prescriptions; unsuppressed state rows only2023Q3: 83,293 prescriptions; unsuppressed state rows only2023Q4: 81,212 prescriptions; unsuppressed state rows only2024Q1: 79,056 prescriptions; unsuppressed state rows only2024Q2: 72,808 prescriptions; unsuppressed state rows only2024Q3: 72,741 prescriptions; unsuppressed state rows only2024Q4: 68,703 prescriptions; unsuppressed state rows only2025Q1: 72,599 prescriptions; unsuppressed state rows only2025Q2: 70,680 prescriptions; unsuppressed state rows only2025Q3: 72,946 prescriptions; unsuppressed state rows only2025Q4: 78,681 prescriptions; unsuppressed state rows only2026Q1: 72,730 prescriptions (latest quarter, preliminary: CMS may revise); unsuppressed state rows only85k0
Top: months the ER capsule name was on the FDA list (Wayback captures of the FDA page). Middle: NADAC per capsule, one line per strength. Where NADAC reported no price for a strength for more than two months, the line breaks and the gap is hatched: we do not bridge missing prices. Bottom: Medicaid prescriptions per quarter. Medicaid volume: 138,072 rows pulled for this drug, 77,203 (56%) suppressed by CMS for small cells and left out, never counted as zero, so every bar is a floor; state XX national rows excluded; the hatched latest quarter is preliminary. Fills also move with Medicaid enrollment, so a change is not by itself evidence of a shortage.

How long do shortages last?

Each step is a drop in the share of FDA shortage listings still running. The dot is this drug.

Share of FDA shortage listings still running after N months, with this drug marked0%25%50%75%100%024487296120months on the FDA listmedian 21 monthsthis listing (ended): 15 mo62% lasted this long
Kaplan-Meier on 397 listings, 2014 to 2026, by ingredient. 18 months have no capture and are bridged by inference. Every listing behind this curve, with the method and a dated correction, is in the shortage length dataset.

What a pharmacy pays per unit

NADAC is the average price retail pharmacies pay, per capsule.

Pharmacy acquisition cost per unit, brand against genericER capsule 120 mg$0.311ER capsule 60 mg$1.34ER capsule 90 mg$1.75ER capsule 180 mg$0.186
Thirty generic 120 mg extended-release capsules is about $9.34 at this benchmark. It is acquisition cost, not a retail price.

Which forms are short

FDA listing by dosage form
FormListed nowMonths listedFDA records (2026-11-05)
ER capsuleNo (last listed February 2020)15none
ER tabletNo0none
tabletNo0none
capsuleNo0none

Price by strength

ER capsule: generic acquisition cost per capsule by strength
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
60 mg$1.34$2.30$0.9482013-11-42%7
90 mg$1.75$2.65$0.9672013-11-34%5-month gap in NADAC reporting7
120 mg$0.311$0.272$1.362013-11+14%21
180 mg$0.186$0.252$0.5172013-11-26%14
240 mg$0.205$0.337$0.5812013-11-39%14
300 mg$0.304$0.456$0.6102017-10-33%8
360 mg$0.315$3.38$8.242014-01-91%5
420 mg$0.998$1.15$1.122020-03-13%1 (single product, not a median)
Tablet: generic acquisition cost per tablet by strength (not on the FDA list)
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
30 mg$0.051$0.102$0.0542013-11-50%8
60 mg$0.072$0.174$0.0942013-11-59%8
90 mg$0.070$0.259$0.1412013-11-73%5
120 mg$0.091$0.315$0.1822013-11-71%4
ER tablet: generic acquisition cost per tablet by strength (not on the FDA list)
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
120 mg$1.01n/a$2.262023-06n/a3
180 mg$1.17$2.16$2.262013-11-46%5
240 mg$1.05$2.48$2.612013-11-58%5
300 mg$1.93n/a$3.312013-11n/a14-month gap in NADAC reporting5
360 mg$1.75$3.44$3.562013-11-49%5
420 mg$2.66n/a$3.932013-11n/a24-month gap in NADAC reporting5
Capsule: generic acquisition cost per capsule by strength (not on the FDA list)
StrengthNow2021 medianFirst monthNow vs 2021HistoryNDCs
120 mg$0.146$0.209$0.3482013-11-30%2
180 mg$0.186$0.252$0.3662013-11-26%2
240 mg$0.205$0.337$0.4782013-11-39%2
300 mg$0.304$0.456$0.7292013-11-33%2
Read the price with care. NADAC is a national survey average of retail pharmacy invoices. It is not a quote, not what any patient paid, and it excludes discounts and rebates. A flat or falling benchmark during a shortage means pharmacies' average invoice cost did not rise, not that every patient could find the drug at that price.
FDA caution. The FDA drug shortage list is updated as manufacturers report and should not be relied on for medical care. Ask a pharmacist or prescriber about supply.

Questions

Is Diltiazem still in shortage?

The ER capsule is not on the FDA shortage list as of 2026-11-05. It was listed from December 2018 to February 2020. FDA says not to rely on the list for medical care; ask a pharmacist.

Did the shortage raise the pharmacy price?

In the benchmark, yes. The NADAC survey average for a generic 120 mg capsule is $0.311 in November 2026, 14% above its 2021 median and 77% below November 2013. NADAC is a national average of retail pharmacy invoices, so it measures what pharmacies pay on average, not what any one patient was charged.

Did Medicaid fills fall during the shortage?

Yes. CMS State Drug Utilization Data shows 78,681 Medicaid-paid ER capsule prescriptions in Q4 2025, 3% fewer than in Q4 2021 (81,165). Those counts are a floor because CMS suppresses small cells, they cover Medicaid only and move with Medicaid enrollment, and they count prescriptions that were filled, not demand that went unmet. A change in fills is not by itself evidence of a shortage.

What does a pharmacy pay for 30 generic 120 mg extended-release capsules?

About $9.34 on the NADAC benchmark ($0.311 per capsule times 30). That is acquisition cost, not a retail price: it excludes dispensing fees, discounts and rebates.

If you are trying to pay for or find this drug

Run a pharmacy, discount card, telehealth or assistance service that helps people pay for medicines? Apply to be evaluated for a page like this one, or hold a disclosed featured slot. Inclusion is earned. A slot is labelled sponsored and never implies a medical endorsement. Building a product on this data? Licence the widget or the data feed.

Cite this page

Figures are calculated from U.S. federal sources (see Data terms below) and rebuilt from dated snapshots. Cite it as:

OmniRx, "Diltiazem: FDA shortage, NADAC acquisition cost and Medicaid utilization", data as of November 2026. https://omnirx.org/drugs/diltiazem

Embed this chart

Free with attribution: paste this where you want the chart. It sizes itself to its content. A small "Powered by OmniRx" link stays in the widget; white-label licences remove it and add your own branding.

<iframe id="lx-drug-diltiazem" src="https://omnirx.org/embed/drug-diltiazem" width="100%" height="640" style="border:1px solid #e2e8f0;border-radius:10px" title="Diltiazem shortage and price timeline by omnirx.org" loading="lazy"></iframe>
<script>addEventListener('message',function(e){if(e.origin!=='https://omnirx.org')return;var d=e.data||{};if(d.type==='lx-height'&&d.slug==='drug-diltiazem'){var f=document.getElementById('lx-'+d.slug);if(f)f.height=d.height;}});</script>

Sources

Data terms. Every source above is published by a U.S. federal agency (CMS or FDA). CMS's data site labels its datasets inconsistently: of the 14 NADAC years, 5 carry the "public domain" label and 9 the "U.S. government works" label; of the 14 State Drug Utilization Data years, 6 carry the "public domain" label and 8 the "U.S. government works" label. We record each dataset's label verbatim and cite the source for every figure. Figures on this page are OmniRx calculations from those datasets, not statements by CMS or FDA, and no agency endorses this page.